Cogent Other Stockholder Equity vs Total Current Liabilities Analysis

COGT Stock

USD 9.58 0.05 0.52%

Cogent Biosciences financial indicator trend analysis is way more than just evaluating Cogent Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cogent Biosciences is a good investment. Please check the relationship between Cogent Biosciences Other Stockholder Equity and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cogent Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.

Other Stockholder Equity vs Total Current Liabilities

Other Stockholder Equity vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cogent Biosciences Other Stockholder Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Cogent Biosciences' Other Stockholder Equity and Total Current Liabilities is 0.81. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Cogent Biosciences, assuming nothing else is changed. The correlation between historical values of Cogent Biosciences' Other Stockholder Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Cogent Biosciences are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Stockholder Equity i.e., Cogent Biosciences' Other Stockholder Equity and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Other Stockholder Equity

Total Current Liabilities

Total Current Liabilities is an item on Cogent Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cogent Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Cogent Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cogent Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cogent Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.At this time, Cogent Biosciences' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.09 in 2024, despite the fact that Enterprise Value Multiple is likely to grow to (2.00).

	2021	2022	2023	2024 (projected)
Interest Income	467K	4.0M	11.3M	11.9M
Net Interest Income	467K	4.0M	11.3M	11.9M

Interest Income Net Interest Income

Cogent Biosciences fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Inventory	Net Invested Capital
Common Stock Shares Outstanding		0.78	0.96	0.79	0.75	0.94	0.69	-0.1	-0.98	0.97	0.19	0.97	0.82	0.75	0.96	0.92	0.17	0.71	0.97	0.76	0.95	0.75	0.45	0.96	-0.81	0.79
Total Assets	0.78		0.81	0.76	1.0	0.71	0.34	-0.59	-0.84	0.64	0.67	0.72	0.81	1.0	0.82	0.59	0.02	0.95	0.86	0.65	0.71	1.0	0.64	0.81	-0.38	0.93
Other Current Liab	0.96	0.81		0.81	0.79	0.93	0.64	-0.17	-0.99	0.95	0.27	0.96	0.74	0.78	0.98	0.88	0.05	0.77	0.99	0.7	0.94	0.78	0.5	0.99	-0.79	0.86
Total Current Liabilities	0.79	0.76	0.81		0.71	0.77	0.66	-0.11	-0.84	0.77	0.19	0.78	0.8	0.71	0.86	0.72	-0.02	0.66	0.81	0.83	0.77	0.72	0.56	0.86	-0.5	0.86
Total Stockholder Equity	0.75	1.0	0.79	0.71		0.67	0.31	-0.66	-0.81	0.6	0.73	0.67	0.78	1.0	0.8	0.53	-0.05	0.97	0.84	0.57	0.67	1.0	0.68	0.79	-0.36	0.93
Property Plant And Equipment Net	0.94	0.71	0.93	0.77	0.67		0.57	0.05	-0.92	0.93	0.05	0.99	0.75	0.66	0.91	0.94	0.34	0.6	0.9	0.84	1.0	0.67	0.27	0.92	-0.75	0.72
Current Deferred Revenue	0.69	0.34	0.64	0.66	0.31	0.57		0.23	-0.67	0.76	-0.18	0.66	0.44	0.32	0.64	0.78	-0.05	0.24	0.63	0.53	0.6	0.32	0.36	0.67	-0.84	0.42
Net Debt	-0.1	-0.59	-0.17	-0.11	-0.66	0.05	0.23		0.2	0.1	-0.99	0.05	-0.25	-0.66	-0.22	0.22	0.51	-0.74	-0.27	0.2	0.06	-0.65	-0.71	-0.19	-0.2	-0.53
Retained Earnings	-0.98	-0.84	-0.99	-0.84	-0.81	-0.92	-0.67	0.2		-0.94	-0.3	-0.95	-0.8	-0.81	-0.99	-0.87	-0.03	-0.79	-1.0	-0.73	-0.93	-0.81	-0.56	-0.99	0.78	-0.88
Accounts Payable	0.97	0.64	0.95	0.77	0.6	0.93	0.76	0.1	-0.94		-0.01	0.97	0.7	0.6	0.92	0.95	0.18	0.56	0.92	0.75	0.94	0.6	0.32	0.94	-0.88	0.69
Cash	0.19	0.67	0.27	0.19	0.73	0.05	-0.18	-0.99	-0.3	-0.01		0.05	0.33	0.73	0.31	-0.13	-0.48	0.8	0.36	-0.11	0.04	0.72	0.73	0.28	0.13	0.61
Non Current Assets Total	0.97	0.72	0.96	0.78	0.67	0.99	0.66	0.05	-0.95	0.97	0.05		0.77	0.67	0.93	0.96	0.29	0.61	0.93	0.82	1.0	0.67	0.31	0.94	-0.81	0.73
Non Currrent Assets Other	0.82	0.81	0.74	0.8	0.78	0.75	0.44	-0.25	-0.8	0.7	0.33	0.77		0.78	0.78	0.66	0.18	0.75	0.78	0.77	0.75	0.78	0.54	0.77	-0.4	0.77
Cash And Short Term Investments	0.75	1.0	0.78	0.71	1.0	0.66	0.32	-0.66	-0.81	0.6	0.73	0.67	0.78		0.79	0.54	-0.04	0.96	0.83	0.58	0.66	1.0	0.68	0.78	-0.36	0.92
Common Stock Total Equity	0.96	0.82	0.98	0.86	0.8	0.91	0.64	-0.22	-0.99	0.92	0.31	0.93	0.78	0.79		0.84	-0.03	0.79	0.99	0.71	0.92	0.8	0.59	1.0	-0.74	0.9
Short Term Investments	0.92	0.59	0.88	0.72	0.53	0.94	0.78	0.22	-0.87	0.95	-0.13	0.96	0.66	0.54	0.84		0.38	0.43	0.85	0.82	0.95	0.54	0.18	0.86	-0.88	0.58
Non Current Liabilities Total	0.17	0.02	0.05	-0.02	-0.05	0.34	-0.05	0.51	-0.03	0.18	-0.48	0.29	0.18	-0.04	-0.03	0.38		-0.22	0.0	0.54	0.33	-0.04	-0.68	-0.02	-0.07	-0.22
Other Current Assets	0.71	0.95	0.77	0.66	0.97	0.6	0.24	-0.74	-0.79	0.56	0.8	0.61	0.75	0.96	0.79	0.43	-0.22		0.82	0.43	0.6	0.97	0.77	0.77	-0.32	0.93
Other Stockholder Equity	0.97	0.86	0.99	0.81	0.84	0.9	0.63	-0.27	-1.0	0.92	0.36	0.93	0.78	0.83	0.99	0.85	0.0	0.82		0.68	0.91	0.84	0.58	0.99	-0.76	0.89
Total Liab	0.76	0.65	0.7	0.83	0.57	0.84	0.53	0.2	-0.73	0.75	-0.11	0.82	0.77	0.58	0.71	0.82	0.54	0.43	0.68		0.83	0.58	0.09	0.71	-0.46	0.6
Property Plant And Equipment Gross	0.95	0.71	0.94	0.77	0.67	1.0	0.6	0.06	-0.93	0.94	0.04	1.0	0.75	0.66	0.92	0.95	0.33	0.6	0.91	0.83		0.67	0.27	0.93	-0.77	0.72
Total Current Assets	0.75	1.0	0.78	0.72	1.0	0.67	0.32	-0.65	-0.81	0.6	0.72	0.67	0.78	1.0	0.8	0.54	-0.04	0.97	0.84	0.58	0.67		0.67	0.79	-0.36	0.92
Short Term Debt	0.45	0.64	0.5	0.56	0.68	0.27	0.36	-0.71	-0.56	0.32	0.73	0.31	0.54	0.68	0.59	0.18	-0.68	0.77	0.58	0.09	0.27	0.67		0.57	-0.25	0.75
Common Stock	0.96	0.81	0.99	0.86	0.79	0.92	0.67	-0.19	-0.99	0.94	0.28	0.94	0.77	0.78	1.0	0.86	-0.02	0.77	0.99	0.71	0.93	0.79	0.57		-0.77	0.89
Inventory	-0.81	-0.38	-0.79	-0.5	-0.36	-0.75	-0.84	-0.2	0.78	-0.88	0.13	-0.81	-0.4	-0.36	-0.74	-0.88	-0.07	-0.32	-0.76	-0.46	-0.77	-0.36	-0.25	-0.77		-0.43
Net Invested Capital	0.79	0.93	0.86	0.86	0.93	0.72	0.42	-0.53	-0.88	0.69	0.61	0.73	0.77	0.92	0.9	0.58	-0.22	0.93	0.89	0.6	0.72	0.92	0.75	0.89	-0.43

Click cells to compare fundamentals

Cogent Biosciences Account Relationship Matchups

Cogent Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	7.6M	11.1M	38.7M	58.7M	79.7M	83.6M
Total Assets	49.4M	250.9M	232.1M	300.8M	313.4M	186.6M
Other Current Liab	7.1M	8.3M	8.9M	18.2M	24.7M	26.0M
Total Current Liabilities	13.2M	13.1M	17.1M	26.8M	38.2M	21.1M
Total Stockholder Equity	31.8M	234.7M	214.2M	255.7M	257.8M	156.1M
Property Plant And Equipment Net	7.2M	4.7M	4.5M	31.1M	30.3M	31.9M
Current Deferred Revenue	1.3M	3.8M	8.0M	1.7M	25.7M	27.0M
Net Debt	(31.4M)	(237.0M)	(216.5M)	(120.2M)	(34.4M)	(36.1M)
Retained Earnings	(123.9M)	(198.7M)	(271.0M)	(411.2M)	(603.6M)	(573.4M)
Accounts Payable	3.2M	732K	3.5M	5.8M	10.7M	11.2M
Cash	37.4M	242.2M	219.7M	139.9M	53.2M	50.6M
Non Current Assets Total	8.8M	6.0M	9.5M	35.8M	42.7M	44.8M
Cash And Short Term Investments	37.4M	242.2M	219.7M	259.3M	265.7M	166.7M
Short Term Investments	12.7M	22.9M	0.0	119.4M	212.5M	223.1M
Liabilities And Stockholders Equity	49.4M	250.9M	232.1M	300.8M	313.4M	186.6M
Non Current Liabilities Total	4.4M	3.2M	831K	18.2M	17.5M	9.5M
Other Current Assets	1.2M	5.4M	5.9M	5.7M	5.1M	3.4M
Other Stockholder Equity	155.6M	322.5M	399.7M	601.2M	801.1M	841.1M
Total Liab	17.7M	16.2M	17.9M	45.1M	55.6M	30.6M
Property Plant And Equipment Gross	7.2M	4.7M	5.0M	32.5M	34.0M	35.7M
Total Current Assets	40.6M	244.9M	222.6M	265.0M	270.8M	170.1M
Accumulated Other Comprehensive Income	(16K)	(12K)	0.0	(104K)	246K	258.3K
Short Term Debt	1.6M	4.1M	4.6M	2.8M	2.8M	3.3M
Net Invested Capital	31.8M	123.8M	128.8M	189.9M	197.8M	107.4M
Net Working Capital	27.3M	231.8M	205.6M	238.1M	232.6M	160.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC